Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man
- PMID: 7259927
- PMCID: PMC1401654
- DOI: 10.1111/j.1365-2125.1981.tb01131.x
Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man
Abstract
1 The 0-24 h urine from hypertensive patients treated with hydralazine (100 mg twice daily) has been analysed by gas chromatography and high pressure liquid chromatography. 2 4-N-Acetylhydrazinophthalazine-1-one (NAcHPZ), s-triazolo [3, 4-a] phthalazine (TP), phthalazinone (PZ) and hydralazine (free, H; acid-labile hydrazones, HH) were detected and assayed. 3 The results indicate that slow acetylators excrete less NAcHPZ and TP than rapid acetylators but more PZ and HH. 4 Free hydralazine was present in low levels and was only detected in some urine samples. 5 The ratios of the metabolites NAcHPZ/HH; TP/HH; NAcHPZ/PZ and PZ/TP are different in the two acetylator phenotypes. 6 It is possible the ratio PZ/TP may be used for determination of acetylator phenotype. 7 It is concluded that hydralazine metabolism is dependent on the acetylator phenotype.
Similar articles
-
Polymorphic acetylation of hydralazine.Clin Pharmacol Ther. 1980 Sep;28(3):350-5. doi: 10.1038/clpt.1980.173. Clin Pharmacol Ther. 1980. PMID: 7408395
-
The oxidative metabolism of hydralazine by rat liver microsomes.Drug Metab Dispos. 1986 Sep-Oct;14(5):549-54. Drug Metab Dispos. 1986. PMID: 2876860
-
Determination of hydralazine metabolites: 4-hydrazino-phthalazin-1-one and n-acetylhydrazinophthalazin-1-one by gas chromatography and s-triazolo[3,4-alpha]phthalazine and phthalazinone by high-performance liquid chromatography.J Chromatogr. 1980 Aug 8;183(2):167-73. doi: 10.1016/s0378-4347(00)81690-4. J Chromatogr. 1980. PMID: 7400275
-
Genetically determined variability in acetylation and oxidation. Therapeutic implications.Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003. Drugs. 1985. PMID: 2859977 Review.
-
Acetylation.Birth Defects Orig Artic Ser. 1990;26(1):43-65. Birth Defects Orig Artic Ser. 1990. PMID: 2224079 Review.
Cited by
-
Drug-related lupus. Incidence, mechanisms and clinical implications.Drug Saf. 1991 Nov-Dec;6(6):431-49. doi: 10.2165/00002018-199106060-00004. Drug Saf. 1991. PMID: 1793523 Review.
-
Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.Eur J Clin Pharmacol. 1983;24(3):301-5. doi: 10.1007/BF00610045. Eur J Clin Pharmacol. 1983. PMID: 6861845
-
Hydralazine-induced lupus: is there a toxic metabolic pathway?Eur J Clin Pharmacol. 1984;27(5):555-9. doi: 10.1007/BF00556891. Eur J Clin Pharmacol. 1984. PMID: 6519160
-
Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.Expert Opin Drug Metab Toxicol. 2021 Jan;17(1):9-21. doi: 10.1080/17425255.2021.1840551. Epub 2020 Nov 3. Expert Opin Drug Metab Toxicol. 2021. PMID: 33094670 Free PMC article. Review.
-
Genotype-Guided Hydralazine Therapy.Am J Nephrol. 2020;51(10):764-776. doi: 10.1159/000510433. Epub 2020 Sep 14. Am J Nephrol. 2020. PMID: 32927458 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases